| Date | Title | Description |
| 19.11.2024 | Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release, Upcoming Webinar Hosted by Xtalks | www.oxb.com
In this free webinar, learn how advanced robotics, digital tools and design of experiments (DoE) are revolutionizing viral vector manufacturing, optimization and quality control (QC) release testing. Attendees will learn about a... |
| 23.09.2024 | Interim Results for the Six Months Ended 30 June 2024 | Press release
OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration progressing across UK, US and Fre... |
| 23.09.2024 | Interim Results for the Six Months Ended 30 June 2024 | Press release
OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024
Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration progressing across UK, US and Fre... |
| 19.08.2024 | Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity, Upcoming Webinar Hosted by Xtalks | www.oxb.com
In this free webinar, learn about enhancing adeno-associated virus (AAV) viral vector quality, focusing on recent breakthroughs in AAV development. Attendees will discover how production duration and location of capsids at harve... |
| 18.06.2024 | Oxford Biomedica issues new shares to secure a £17m investment | - |
| 20.02.2023 | Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 | Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly created position of V... |
| 15.09.2022 | OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 | OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A GLOBAL VIRAL VECTOR LEADER
Oxford, UK – 15 September 2022: Oxford Biomedica plc (“Oxford Biomedica”... |
| 04.02.2022 | Oxford Biomedica raises £39m after snapping up majority stake in US firm | Oxford Biomedica, which helped AstraZeneca with its Covid-19 vaccine manufacturing, has raised £39.4m in a share placing. |
| 14.12.2021 | Oxford Biomedica : Appoints Catherine Moukheibir as Non-Executive Director | Oxford, UK - [14] December 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independ... |
| 08.11.2021 | Sanofi eyes a gene therapy prospect and commits $60M for a stake, potential rights | Sanofi’s gene therapy pipeline is not as deep as that of some of its industry peers, and the company has been shuffling programs in the past year as it tries to find the right mix. The France-based pharmaceutical giant has found a possible ... |
| 19.10.2021 | Oxford Biomedica : Boehringer Ingelheim Exercises Option | Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
Oxford, UK - 19 October 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the... |
| 23.09.2021 | Serum Institute to invest $68 million in UK vaccine maker Oxford Biomedica | Serum Life Sciences, a unit of SII, will pick up a 3.9% stake in Oxford Biomedica as part of the deal
Vaccine maker Serum Institute of India (SII) will invest £50 million ($68 million) in OxfordBiomedica to help fund the development of a pl... |
| 23.09.2021 | Oxford Biomedica sees new investment for manufacturing; Twist gets a partner to help build out discovery libraries | Oxford Biomedica has landed some new cash.
The British gene and cell therapy biotech announced Wednesday it has secured an investment “just over” £50 million from the Serum Institute of India’s investment arm. Funds are ex... |
| 22.09.2021 | Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 | OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
Oxford Biomedica delivers record first half results
Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading ge... |
| 22.09.2021 | Oxford Biomedica : announces strategic investment by Serum Life Sciences Ltd | The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (... |
| 22.09.2021 | Oxford Biomedica : Interim results for the six months ended 30 June 2021 | Oxford Biomedica delivers record first half results
Oxford, UK - 22 September 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces interim resu... |
| 19.04.2021 | OXFORD BIOMEDICA PLC
Oxford Biomedica : Earnings Document | Press release
Oxford Biomedica plc
Preliminary results for the year ended 31 December 2020
Saving Lives
Oxford, UK - 15 April 2021: Oxford Biomedica plc (LSE: OXB), ("OXB" or "the Group"), a leading cell and gene therapy... |
| 19.04.2021 | Oxford Biomedica : Earnings Document | Press release
Oxford Biomedica plc
Preliminary results for the year ended 31 December 2020
Saving Lives
Oxford, UK - 15 April 2021: Oxford Biomedica plc (LSE: OXB), ("OXB" or "the Group"), a leading cell and gene therapy... |
| 15.04.2021 | OXFORD BIOMEDICA PLC
Oxford Biomedica : Preliminary results for the year ended 31 December 2020 | Oxford Biomedica plc
Preliminary results for the year ended 31 December 2020 Saving Lives
Oxford, UK - 15 April 2021: Oxford Biomedica plc (LSE: OXB), ('OXB' or 'the Group'), a leading cell and gene therapy group, today announces its prelim... |
| 08.04.2021 | Manufacturing briefing: After J&J-Emergent mixup, fewer doses expected in US next week; Boehringer taps Oxford for viral vectors | Americans will see a significant drop in J&J Covid-19 vaccines allocated next week, according to data from the CDC.
A report from Reuters noted that just 785,500 doses will be doled out, compared to 4.95 million this we... |
| 06.04.2021 | OXFORD BIOMEDICA PLC
Oxford Biomedica : signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors | Oxford, UK - 6 April, 2021: Oxford Biomedica plc (LSE:OXB) ('Oxford Biomedica' or 'the Group'), a leading gene and cell therapy group, announced today that it has signed a new three year Development & Supply Agreement ('DSA') with Boehr... |
| 09.11.2020 | PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration | PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration
09-11-2020
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a le... |
| 17.09.2020 | OXFORD BIOMEDICA PLC
Oxford Biomedica : interim results for thesix months ended 30 June 2020 | Oxford, UK - 17 September 2020: Oxford Biomedica plc ('Oxford Biomedica' or 'the Group') (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2020.
FINANCIAL HIGHLIGHTS
• Revenu... |
| 17.09.2020 | OXFORD BIOMEDICA PLC
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 | OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020
Oxford, UK – 17 September 2020: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim r... |
| 17.09.2020 | OXFORD BIOMEDICA PLC
Oxford Biomedica : OXB Interim Results FY20 RNS FINAL.pdf | Page 1 of 29
OXFORD BIOMEDICA PLC
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020
Oxford, UK - 17 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy... |
| - | Sanofi eyes a gene therapy prospect and commits $60M for a stake, potential rights | Sanofi’s gene therapy pipeline is not as deep as that of some of its industry peers, and the company has been shuffling programs in the past year as it tries to find the right mix. The France-based pharmaceutical giant has found a possible ... |
